1. Introduction {#sec1}
===============

Liver fibrosis results from sustained injury, which can be inflicted by various factors such as viruses, drugs, alcohol, metabolic diseases, and autoimmune attacks \[[@B1]\]. Prolonged exposure to these harmful factors causes hepatocyte apoptosis, inflammatory cell recruitment, endothelial cell impairment, and, lastly, activation of hepatic stellate cells, the major cells involved in liver fibrosis. Liver fibrosis is a kind of scar tissue formation in response to liver damage \[[@B2]--[@B9]\]. Histologically, it is caused by an imbalance between extracellular matrix synthesis and degradation \[[@B10]--[@B12]\].

Liver cirrhosis is a condition where scar tissue replaces the healthy tissue of the liver and regenerative nodules with surrounding fibrous bands develop as a result of the injury \[[@B13]\]. Cirrhosis is the common end of progressive liver disease of various causes, resulting in chronic liver failure entailing complications such as hepatic encephalopathy, spontaneous bacterial peritonitis, ascites, and esophageal varices \[[@B14]\]. Unfortunately, the majority of cases are usually in an irreversible state when diagnosed. Despite current advancements in its management \[[@B15], [@B16]\], cirrhosis was the 14th leading cause of death worldwide in 2012 \[[@B17]\]. Orthotopic liver transplantation is known to be the only definite solution to end-stage cirrhosis.

However, several problems preclude the prevalent application of the procedure, including immunological rejection and the scarcity of donor sources \[[@B18]\].

In fact, the liver has an inherent regenerative capacity to a substantial degree \[[@B19]\], and, thus, the cessation of those harmful factors may prevent further progression of fibrosis and reverse the situation in some cases \[[@B20]\]. In cases where hepatocyte proliferation is insufficient for recovery from liver injury, bipotent resident liver progenitor cells (LPC) are activated and participate in liver regeneration by differentiating into hepatocytes and biliary epithelial cells \[[@B19], [@B21]--[@B23]\]. However, fibrosis is inevitable when regeneration is exceeded by destruction. Clinical signs of liver failure usually appear after about 80 to 90% of the parenchyma has been destroyed.

Hepatocyte transplantation has been proposed as an alternative approach to transplantation, since hepatocytes have been proven to be strongly associated with liver repair \[[@B24]--[@B28]\]. While hepatocyte transplantation is safe in humans, its applicability remains limited due to organ availability, failure of donor engraftment, weak viability in cell culture, and vulnerability to cryopreservation damage \[[@B25], [@B26], [@B29]--[@B32]\].

Instead of hepatocytes, the transplantation of stem cells has shown therapeutic potential for liver function improvement according to recent experimental studies and human studies \[[@B20], [@B26], [@B33]--[@B40]\]. Although they remain unclear, the major potential mechanisms have been proposed as a twofold; one is the improvement of the microenvironments through paracrine effects, and the other is the replacement of functional hepatocytes \[[@B20]\].

To date, several kinds of stem cells have been investigated for their therapeutic feasibility and clinical potential in liver cirrhosis \[[@B41]--[@B43]\]. The present article briefly reviews the current literature according to the types of stem cells and discusses the future perspectives of stem cell-based therapy in liver cirrhosis.

2. Sources of Stem Cells {#sec2}
========================

Hepatocytes obtained via autopsy of patients who received bone marrow transplantation suggested that they are pluripotent cells in bone marrow \[[@B44], [@B45]\]. Currently, at least three types of bone marrow-derived cells are known to differentiate into hepatocyte-like cells (HLCs): hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and endothelial progenitor cells (EPCs), though early infusion trials did not discriminate the origins of those cells from bone marrow-derived stromal cells with some improvement \[[@B32], [@B46]--[@B52]\]. A large number of preclinical studies have proven the feasibility of HSCs, MSCs, and EPCs to restore hepatic function in models of liver injury \[[@B53]--[@B57]\]. In addition, other stem cells including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can also be differentiated into HLCs \[[@B58]--[@B60]\]. HLCs can contribute to the remodeling of cirrhotic liver \[[@B20], [@B61]--[@B68]\].

2.1. Hematopoietic Stem Cells {#sec2.1}
-----------------------------

HSCs are the predominant population of stem cells within bone marrow and express CD34 as the cell surface marker. They can renew themselves and differentiate into progenitor cells \[[@B69], [@B70]\]. HSCs can easily be made to leave the bone marrow and circulate into the blood. The mobilization of HSCs resident in bone marrow can be brought about at a low magnitude through tissue injury \[[@B71], [@B72]\] or in high amounts after artificial priming \[[@B73], [@B74]\]. Granulocyte-colony stimulating factor is the most widely studied and widely used mobilizing agent \[[@B75]--[@B80]\].

HLCs derived from HSCs have been demonstrated to contribute to liver regeneration \[[@B65], [@B81]--[@B83]\]. In general, two mechanisms were proposed with substantial support. One was the de novo generation of hepatocytes through trans-differentiation, and the other was the genetic reprogramming of resident hepatocytes through cell fusion \[[@B45], [@B46], [@B84]\]. However, the infused HSCs do not seem to be a primary source of newly generated hepatocytes \[[@B85], [@B86]\]. Rather, their roles are likely to be associated with macrophages, which produce collagenases, phagocytose dead cells, and facilitate liver regeneration \[[@B87]--[@B89]\]. Therefore, the clinical benefit of HSC therapy occurs through paracrine signaling interactions involving various cytokines and growth factors \[[@B86], [@B90], [@B91]\]. Furthermore, HSCs likely stimulate neoangiogenesis \[[@B92]\].

2.2. Endothelial Progenitor Cells {#sec2.2}
---------------------------------

EPCs are immature endothelial cells that can be found in both peripheral blood vessels and bone marrow. They arise from hemangioblasts and participate in the neovascularization of damaged tissue throughout the whole body \[[@B93]--[@B99]\]. Due to their common expression of CD34, EPCs and HSCs are assumed to have a common precursor \[[@B94], [@B100]--[@B106]\]. However, EPCs are likely to be differentiated from various cell lineages, as evidenced by their diverse surface markers \[[@B102], [@B104], [@B107]--[@B113]\].

The transplantation of EPCs led to the suspension of liver fibrosis by suppressing activating HSCs, according to an animal study \[[@B55]\]. They also promoted hepatocyte proliferation and increased matrix metalloproteinase activity \[[@B114]\]. These effects were associated with increased secretion of growth factors \[[@B115]--[@B117]\].

2.3. Mesenchymal Stem Cells {#sec2.3}
---------------------------

MSCs are a rarer population in bone marrow compared to HSCs, which are capable of self-renewal and differentiation into HLCs as well as cell types of mesenchymal origin \[[@B68], [@B118]--[@B128]\]. Traditionally, MSCs have frequently been isolated from bone marrow \[[@B129]\], but, recently, they have been obtained from many other tissues including umbilical cord blood, adipose tissue, and placenta \[[@B130]--[@B142]\]. There seems to be source-dependent differences among MSCs \[[@B143]\].

As a therapeutic advantage, MSCs can easily be expanded ex vivo without losing their differentiation potential, and they can also be migrated to the injured areas in response to homing signals \[[@B1]\]. Furthermore, the MSCs have immunomodulatory properties \[[@B144]--[@B156]\], through both adaptive and innate immune systems \[[@B157], [@B158]\], and secrete a variety of trophic factors such as growth factors and cytokines beneficial for liver regeneration \[[@B159]--[@B164]\]. Some of these trophic factors are known to revive hepatocytes reaching their replicative senescence \[[@B38], [@B165], [@B166]\]. With these advantages as a cell therapy source, the MSCs are the most widely studied stem cells, both experimentally and clinically \[[@B59], [@B167]--[@B174]\].

The precise therapeutic mechanisms of MSCs in liver regeneration have yet to be sufficiently elucidated. Accumulating evidence strongly supports the inference that the effects of MSCs are mediated mostly via paracrine mechanisms rather than transdifferentiation \[[@B175]--[@B179]\], although the infused bone marrow-derived MSCs (BM-MSCs) have been shown to engraft into host livers and ameliorate fibrosis in experimental animal models of liver fibrosis \[[@B54], [@B180]--[@B183]\]. MSC transplantation has also demonstrated preclinical efficacy in mitigating liver fibrosis as in other organs \[[@B53], [@B54], [@B181], [@B184]--[@B187]\]. Strategies to enhance the effects of MSC in cirrhosis have been investigated, including the facilitation of transdifferentiation into functional hepatocytes \[[@B59], [@B68], [@B120], [@B168], [@B188]\]. Interestingly, however, the in vivo transdifferentiation of MSCs into hepatocytes has been rarely observed in animal models \[[@B54], [@B189]--[@B192]\]. Rather, the MSCs downregulate proinflammatory and fibrogenic cytokine activity, stimulate hepatocellular proliferation, and promote collagen degradation by matrix metalloproteinase \[[@B53], [@B54], [@B181], [@B190]--[@B193]\]. The paracrine effects modulate the functioning of activated hepatic stellated cells \[[@B56], [@B194], [@B195]\]. Evidence from treatment with MSC-conditioned medium reconfirmed the paracrine effects of MSCs such as the increased proliferation and reduced apoptosis of hepatocytes subsequent to the upregulation of several anti-inflammatory and antifibrotic cytokines \[[@B196], [@B197]\]. How each of these signaling molecules individually contributes to hepatic regeneration, however, remains to be further elucidated \[[@B46]\].

2.4. Embryogenic Stem Cells {#sec2.4}
---------------------------

Thomson et al. derived and characterized human ESCs from the inner mass of a blastocyst for the first time in 1998 \[[@B198]\]. ESCs have pluripotency and can differentiate into hepatocyte-like cells, which possess some properties of mature hepatocytes \[[@B199]--[@B205]\]. Hepatocytes generated from ESCs in vitro and hepatocytes differentiated from ESCs have been demonstrated to express a number of hepatocyte-related genes and mimic hepatic functions. ESC-derived hepatocytes bear the typical morphology of mature hepatocyte and colonized liver tissue upon transplantation. The cardinal pathways associated with activin A and Wnt3a and FGF signaling are essential for ESC to differentiate into hepatic lineage \[[@B200], [@B206]--[@B217]\]. ESC-derived hepatocyte-like cells promoted the cell recovery of injured liver by cell replacement \[[@B201], [@B210], [@B218], [@B219]\] and paracrine mechanism to stimulate endogenous regeneration. However, it still remains unclear whether ESCs-derived hepatocytes have the origin of definitive endoderm or primitive endoderm. The recent study using ESCs combined with MSCs showed promising results \[[@B201], [@B220]\]. Human ESCs are likely resistant to cryopreservation, which mature hepatocytes can hardly endure. Studies using ESCs have provided the molecular basis of hepatocyte differentiation. Despite the promising results, the application of human ESCs has always been precluded by practical and ethical barriers.

2.5. Induced Pluripotent Stem Cells {#sec2.5}
-----------------------------------

The iPSCs were first developed by Dr. Yamanaka from mouse fibroblasts in 2006, which were reprogrammed into a state of pluripotency like that of ESCs \[[@B98]\]. These iPSCs have been reported to be differentiated to neuron cells \[[@B221]\], neurospheres \[[@B222]\], cardiomyocytes \[[@B223]--[@B225]\], hematopoietic and endothelial cells \[[@B226]\], and insulin-secreting islet-like clusters \[[@B227]\]. A number of protocols to differentiate iPSCs into HLCs have been described \[[@B60], [@B228]--[@B242]\]. Unfortunately, the iPSC-derived HLCs showed minimal activity, reaching around 0.3 to 10% of the activity of primary hepatocytes \[[@B231]\].

In animal experiments, the iPSC-derived HLC transplantation halted lethal fulminant hepatic failure, promoted regeneration, and improved function \[[@B234], [@B235], [@B243]--[@B245]\]. Due to immunosuppression and possible unlimited supply, the patient-corrected human iPSCs have great potential to be utilized in personalized cell therapy \[[@B230], [@B246], [@B247]\]. However, several issues regarding iPSC usage should be properly addressed prior to clinical application, including teratoma formation and tumorigenicity, controversy about immunogenicity, long-term safety and efficacy, and optimal reprogramming and manufacturing processes \[[@B248]--[@B250]\].

2.6. Other Cells {#sec2.6}
----------------

Fetal hepatic progenitor cells have been of interest due to their ease of isolation, high proliferation rate, superior repopulation capacity, lower immunogenicity, and resistance to cryopreservation in contrast to adult counterparts \[[@B251]--[@B256]\]. Annex stem cells derived from umbilical cord, placenta, and amniotic fluid have easily accessible sources, but they can be categorized as MSCs with respective differences according to their origin \[[@B257]--[@B261]\].

3. Clinical Trials Using Stem Cell-Based Therapy {#sec3}
================================================

Early autologous bone marrow-derived stem cell transplantation resulted in amelioration of liver injury and functional improvements, and they probably included a mixed cell population of HSCs, MSCs, and EPCs \[[@B53], [@B55], [@B82], [@B124], [@B262], [@B263]\]. A number of single-arm, phase I clinical studies with small samples have been performed and have shown some promise in patients with liver cirrhosis \[[@B31], [@B48], [@B49], [@B123], [@B264]--[@B270]\]. The infusion of bone marrow-derived stem cells has sometimes been used as a supportive measure for patients with partial hepatectomy \[[@B271]--[@B273]\]. Although the precise mechanisms are still unresolved, the findings from those studies with small sample sizes have provided assurance that no critical complications occurred after the procedures. Furthermore, the posttransplantation incidence of hepatocellular carcinoma was not increased despite the enduring concern \[[@B68], [@B274], [@B275]\].

A trial using human fetal liver-derived stem cells enrolling 25 patients with cirrhosis demonstrated improved mean model for end-stage liver disease (MELD) scores \[[@B276]\], although long-term outcomes were not properly reported \[[@B277]\]. There have been several clinical studies using HSCs with promising results \[[@B278]--[@B281]\] since Pai et al. \[[@B37]\] reported that the autologous infusion of CD34+ cells improved the serum albumin level and the Child-Pugh score. However, most results have shown only temporary effects and there still remains many questions yet to be answered \[[@B280]\].

The most frequently studied stem cells are the MSCs; thus, their mechanisms of actions are also better understood. In particular, BM-MSCs have been prevalently utilized. In two early pilot studies, autologous injections of BM-MSCs in a few patients were reported to result in improvement of liver function \[[@B35], [@B267]\]. The safety and short-term efficacy of BM-MSCs were evidenced in two groups of 20 patients each, which showed significantly improved Child-Pugh and MELD scores \[[@B47]\]. Subsequent studies continued to confirm the efficacy of BM-MSC transplantation in varying sizes of samples \[[@B282]--[@B285]\]. Notably, one randomized controlled trial using autologous MSCs in cirrhotic patients failed to demonstrate beneficial effects, in contrast to the prior reports \[[@B286]\].

The transplanted cells were mostly infused intravenously, except in three studies using the hepatic artery \[[@B284], [@B285]\] and one featuring direct injection into the spleen \[[@B282]\]. Not a small variation existed in the numbers of infused cells and the administration frequencies. Although the overall study qualities did not surpass the level of moderate or poor, the results seemed promising in terms of MELD scores and liver function improvements \[[@B1]\]. Specifically, most studies did not include histologic evaluations \[[@B287]\].

As other kinds of MSCs, umbilical cord-derived MSCs (UC-MSCs) were evaluated in clinical trials. UC-MSC infusion was well tolerated and resulted in significant functional improvement and increased survival rates \[[@B288]--[@B290]\].

To summarize, stem cell trials in patients with liver cirrhosis have demonstrated generalized functional improvements. In addition, improvements were also found in the MELD and Child-Pugh scores. Unfortunately, these beneficial effects were attenuated with time or were not measured. Therefore, it can be temporarily concluded that treatment using stem cells might be slightly superior to current conventional treatment according to two systematic reviews \[[@B1], [@B42]\] ([Table 1](#tab1){ref-type="table"}).

4. Discussion {#sec4}
=============

Liver cirrhosis is a major cause of mortality and incurs great healthcare burdens across the world \[[@B291]--[@B294]\]. Liver transplantation is the only effective treatment. The survival rate after liver transplantation has progressively increased and the rate of survival after one year of surgery is currently 83% after one year. However, the shortage of organs is a serious problem contributing to the increasing mortality rate of patients on the waiting list \[[@B295], [@B296]\]. Allogeneic hepatocyte transplantation \[[@B297], [@B298]\] also entails limited availability with only modest benefits reported \[[@B26], [@B299], [@B300]\].

Efforts have been made to develop antifibrotic therapies. Unfortunately, there are no antifibrotic drugs available in a current clinical setting \[[@B301]--[@B303]\] even if several reports have been published from preclinical and clinical studies \[[@B304]--[@B306]\]. The targets of the drug are primarily associated with the activities of hepatic stellate cells: the downregulation of cell activation \[[@B307]--[@B310]\], neutralization of fibrogenic and proliferative cell responses \[[@B311]--[@B313]\], promotion of cell apoptosis \[[@B314]\], and promotion of matrix degradation \[[@B315], [@B316]\]. Clinical studies have, however, failed to yield meaningful results compared with preclinical studies \[[@B287], [@B317]--[@B319]\].

In this regard, stem cell-based therapy is considered a promising therapeutic alternative based on the discrepancy between the demand and supply of donor livers for transplantation. Stem cell clinical trials have resulted in promising outcomes \[[@B20], [@B209], [@B230], [@B246], [@B277], [@B320]--[@B325]\]. There are advantages and disadvantages depending on which source of stem cells is used in the cell-based therapies. For example, ethical issues and behavioral uncertainties in vivo are major problems of ESCs or iPSCs to be used clinically although they are the most capability of producing HLCs \[[@B20]\]. Teratoma formation and the use of immunomodulatory drugs are other concerns of stem cell uses. For all kinds of stem cell-based therapies, the progressive liver fibrosis and hepatocellular carcinoma are still the fearful medium- or long-term adverse effects. Prior to clinical use, the in vivo safety should be confirmed including toxicity and tumorigenicity. Regulatory challenges and financial burden cast somewhat different kinds of translational barrier.

Among stem cells of various origins, MSCs have attracted attention due to their advantages and have been extensively investigated in experimental studies and in clinical trials. Nevertheless, there are still a number of issues to be addressed. First, the ideal delivery route of MSCs has not been elucidated, and it is unstandardized in clinical trials to date. MSCs differentiate into myofibroblasts instead of hepatocytes depending on the injection route \[[@B326], [@B327]\]. The optimal dose and number of injections are another practical issue when comparing the results from clinical trials. In addition, sophisticated methods of tracking engrafted MSCs are still lacking. Therefore, it is impossible to predict the fate of transplanted cells, although the survival duration is important for sustained efficacy \[[@B328]--[@B330]\]. Recently, labeling cells with superparamagnetic iron oxide nanoparticles and reporter genes have been suggested with advanced imaging technologies \[[@B331]--[@B336]\]. Finally, the quality of the clinical studies reported to date is far from sufficient to reach a definite conclusion. Patient enrollment must differentiate clearly between patients with compensated cirrhosis and patients with impaired function. Only randomized controlled designs can assess the reliable clinical benefit. Long-term follow-up and histologic evidence should be recommended in cases where they are available \[[@B42], [@B250], [@B337]\].

With advances in novel biotechnology, strategies have been devised to enhance the effects of stem cell-based therapy. For example, the microencapsulation of MSCs in microspheres was proposed to evade unwanted differentiation into myoblasts \[[@B338]\]. To promote the homing of MSCs, the use of MSCs modified by liver-specific receptors has been suggested \[[@B339]\]. Genome editing using CRISPR/Cas9 is a very promising technology widely used in current functional genomics \[[@B18], [@B340], [@B341]\]. The three-dimensional culture technique is another example for providing an expansion and differentiation platform for hepatocytes \[[@B342], [@B343]\].

Rapidly developing iPSC technologies provide an unprecedented opportunity for researchers and clinicians \[[@B344]\]. Recent studies have shown that iPSC-derived hepatocytes can be used for the investigation of the genetic and molecular mechanisms of liver disorders \[[@B240], [@B242], [@B244], [@B345]--[@B356]\]. They can be utilized for multiple applications, including drug safety screening of new drugs \[[@B214], [@B357]--[@B359]\] and disease modeling \[[@B240], [@B360]\]. Disease-specific iPSCs could provide invaluable opportunities to elucidate the pathologic mechanism of disease and develop curative treatment options.

5. Conclusion {#sec5}
=============

Liver fibrosis progresses to cirrhosis, which is the result of the extracellular matrix deposition in the parenchyma. Curative treatment for cirrhosis is currently limited to orthotopic liver transplantation, and a worldwide shortage of donor organs results in the deaths of patients waiting for organs. Stem cell-based therapy has emerged as a promising alternative with accumulating evidence from experimental and clinical studies. Varieties of stem cells including MSCs, HSCs, EPCs, ESCs, and iPSCs have been investigated for their feasibility and/or clinical potentials. Among them, MSCs have been most studied and are relatively well understood. A primary mechanism of action has been proposed as paracrine effects rather than transdifferentiation. The results from clinical trials seem very promising from the perspectives of functional improvement and clinical parameters. However, long- term efficacy has not yet been proven, and standardized trial protocols are needed. Novel technologies are expected to overcome the current hurdles related to clinical application of stem cell-based therapy.
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Main clinical trials of stem cell therapy for liver cirrhosis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial number                                                      Study phase (type)                                  Cell source      \#   Eligibility criteria                                                                                                 Primary outcome measure                                               Secondary outcome measure                                                         Time frame                   Start date   End date                           Location
  ----------------------------------------------------------------- --------------------------------------------------- ---------------- ---- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------- ------------ ---------------------------------- ----------
   [NCT01875081](https://clinicaltrials.gov/ct2/show/NCT01875081)   Phase II (randomized open)                          BM-MSC           72   Histologically or clinically diagnosed as alcoholic liver cirrhosis \                                                Histopathological evaluation                                          Histopathological evaluation score, MELD score, Child-Pugh grade, and so on       6 months                     2012.11      2016.03 (completed)                Korea
                                                                                                                                              Classified as Child-Pugh grade B or C                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT02943889](https://clinicaltrials.gov/ct2/show/NCT02943889)   Phase I/II (nonrandomized open)                     BM-MSC           40   Decompensated liver cirrhosis Child class b or c                                                                     Improvement of liver function in form of improvement in Child score   Postpone or overcome liver transplantation complications                          6, 24 months                 2016.10      2017.08 (not yet recruiting)       None

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT02786017](https://clinicaltrials.gov/ct2/show/NCT02786017)   Phase I/II (randomized double-blinded controlled)   UC-MSC           40   Subjects who are decompensated cirrhosis of any cause \                                                              Change in the model for end-stage liver disease (MELD) score          Change in Child-Pugh score, clinical laboratory parameters of liver function      1 and 3 days \               2016.05      2018.12 (recruiting)               China
                                                                                                                                              Child-pugh score ≥7                                                                                                                                                                                                                                                          1 and 2 weeks \                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                           1, 3, 6, 12, and 24 months                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01591200](https://clinicaltrials.gov/ct2/show/NCT01591200)   Phase II (randomized open)                          AlloMSC          40   Child class B or C, Child-Pugh scores of ≥7 and \<14 \                                                               Safety                                                                Liver function improvement, Child-Pugh score, MELD score, SF36-QOL, and so on     24 months                    2012.06      2016.04 (completed)                India
                                                                                                                                              MELD scores of at least 10                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01120925](https://clinicaltrials.gov/ct2/show/NCT01120925)   Phase I/II \                                        BM-MSC           30   MELD score of 12 or Child score B or C \                                                                             Liver function test                                                   Cirrhosis mortality                                                               6 months                     2010.05      2013.07 (completed)                Iran
                                                                    (randomized quadruple blind controlled)                                   Serum ALT 1/5 times more than normal                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT00420134](https://clinicaltrials.gov/ct2/show/NCT00420134)   Phase I/II \                                        MSC              30   MELD score of at least 10 \                                                                                          Liver function test \                                                 Cirrhosis mortality                                                               6 months                     2006.02      2009.06 (completed)                Iran
                                                                    (randomized single- \                                                     Patent portal vein on color Doppler examination of the live \                                                        MELD score                                                                                                                                                                                                                           
                                                                    blinded)                                                                  Normal alpha-feto protein serum levels                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01013194](https://clinicaltrials.gov/ct2/show/NCT01013194)   Phase I/II (nonrandomized open)                     FLC              25   A score ≥ B8 based on the Child-Pugh-Turcotte classification and/or MELD score ≥ 14                                  Survival                                                              Analysis of Child-Pugh score, meld score from baseline to 1-year follow-up        6 and 12 months              2007.02      2011.07 (completed)                Italy

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01342250](https://clinicaltrials.gov/ct2/show/NCT01342250)   Phase I/II (randomized open)                        UC-MSC           20   Decompensated liver cirrhosis, Child-Pugh B/C (7--12 points) or Meld score ≦ 21.                                     Survival                                                              Liver function improvement, Child-Pugh score, MELD score, SF36-QOL, and so on     24 months                    2010.10      2011.10 (completed)                China

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT02652351](https://clinicaltrials.gov/ct2/show/NCT02652351)   Phase I (open)                                      UC-MSC           20   Clinical, radiological, or biochemical evidence of liver cirrhosis                                                   Severity of adverse events                                            Hepatic function, liver fibrosis index                                            1, 3, 6, and 12 months       2016.03      2016.10 (recruiting)               China

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01147380](https://clinicaltrials.gov/ct2/show/NCT01147380)   Phase I (nonrandomized open)                        NK               18   Subjects who need to meet the liver transplant eligibility criteria \                                                Side effect of cadaveric donor liver NK cell infusion                 NK cell infusion-related toxicity, anti-HCC, HCV effect                           12 and 24 months             2010.06      2014.12 (completed)                USA
                                                                                                                                              Cardiac and pulmonary function                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT03254758](https://clinicaltrials.gov/ct2/show/NCT03254758)   Phase I/II (open)                                   AD-MSC           15   Chronic hepatitis C or nonalcoholic steatohepatitis (NASH) \                                                         Child-Pugh score, safety profile                                      Child-Pugh score, safety profile                                                  6 months                     2017.07      2018.12 (recruiting)               Japan
                                                                                                                                              Child-Pugh grade B liver cirrhosis                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01333228](https://clinicaltrials.gov/ct2/show/NCT01333228)   Phase I/II (open)                                   BM-EPC           14   Liver cirrhosis (Child-Pugh 8 or above)                                                                              Safety and tolerability                                               Effect on liver function, portal hypertension, complications of liver cirrhosis   12 months                    2012.06      2015.03 (completed)                Spain

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01503749](https://clinicaltrials.gov/ct2/show/NCT01503749)   Phase I (randomized \                               PB-MNC (G-CSF)   9    Advanced liver cirrhosis with Child-Pugh score 8 or 9                                                                Severe adverse events                                                 Change in Child-Pugh score and MELD score                                         1--4 weeks \                 2012.01      2014.08 (completed)                \-
                                                                    open)                                                                                                                                                                                                                                                                                                                                                  2--6 months                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT00713934](https://clinicaltrials.gov/ct2/show/NCT00713934)   Phase I/II (randomized single- \                    BMMNC \          7    Liver biopsy showing histological cirrhosis, grade B or C (Child-Pugh score) liver cirrhosis in sonography study \   Liver function test \                                                 Cirrhosis mortality                                                               6 months                     2008.01      2009.02 (completed)                Iran
                                                                    blinded)                                            BMHSC                 Liver crrhosis in sonography study                                                                                   MELD score                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT02297867](https://clinicaltrials.gov/ct2/show/NCT02297867)   Phase I (open)                                      ADSC             6    Investigators without HBV, HCV, HIV, syphilis, and so on                                                             MELD                                                                  None                                                                              1--6 months                  2015.07      2018.01 (active, not recruiting)   Taiwan

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT02705742](https://clinicaltrials.gov/ct2/show/NCT02705742)   Phase I/II (open)                                   AD-MSC           5    Clinical, radiologic, and pathologically proven liver cirrhosis due to HCV hepatitis                                 All cause mortality                                                   \-                                                                                12 months                    2016.01      2017.12 (recruiting)               Turkey

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   [NCT01454336](https://clinicaltrials.gov/ct2/show/NCT01454336)   Phase I (open)                                      BM-MSC           3    Approved cirrhosis by elastography, biopsy, sonography                                                               ALT, AST, serum albumin, liver fibrosis                               Progression of fibrosis                                                           12 months                    2010.06      2013.07 (completed)                Iran
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\#^Number of enrollments; MELD, model for end-stage liver disease; UC-MSC, umbilical cord mesenchymal stem cell; AlloMSC, allogeneic MSC; FLC, fetal liver cell; BM-EPC, bone marrow-derived endothelial progenitor cells; PB-MNC, peripheral blood mononucleated cells; BMHSC, bone marrow CD133+ hematopoietic stem cell.
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